Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Healthcare Biotechnology
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Reports Third Quarter 2015 Financial Results

Business Wire November 10, 2015

Kamada to Host Third Quarter 2015 Financial Results Conference Call on November 10, 2015

Business Wire November 5, 2015

Kamada Announces Third Extension of Strategic Agreement with Baxalta

Business Wire October 16, 2015

Kamada to Present at September Investment Conferences

Business Wire September 8, 2015

Kamada Appoints Michael Berelowitz, M.D. to its Board of Directors

Business Wire August 4, 2015

Kamada Reports Second Quarter 2015 Financial Results

Business Wire July 30, 2015

Kamada to Host Second Quarter 2015 Financial Results Conference Call on July 30, 2015

Business Wire July 24, 2015

Kamada Reports Revenue for First Half 2015 in Line with Plans

Business Wire July 8, 2015

Kamada Announces Publication in Pediatric Diabetes

Business Wire July 6, 2015

Kamada Granted Key New Patent for Inhaled AAT and eFlow® Nebulizer System in Israel

Business Wire July 1, 2015

Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection

Business Wire June 22, 2015

Kamada Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency

Business Wire May 20, 2015

Kamada Reports First Quarter 2015 Financial Results

Business Wire May 12, 2015

Kamada to Host First Quarter 2015 Financial Results Conference Call on May 12, 2015

Business Wire May 8, 2015

Kamada to Present Key Results from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin During the American Thoracic Society (ATS) 2015 International Conference

Business Wire May 6, 2015

Kamada Announces Executive Management Changes

Business Wire April 28, 2015

Kamada Receives Allowance for Key Canadian Patent for Large Scale Production and Use of Proprietary Alpha-1 Proteinase Inhibitor

Business Wire April 1, 2015

Kamada Awarded European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease

Business Wire March 23, 2015

Kamada Strengthens Leadership Team with the Addition of Vice President-Medical Director

Business Wire March 11, 2015

Kamada Reports 2014 Fourth Quarter and Full Year Financial Results

Business Wire February 11, 2015